Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia
Metrics: PDF 2451 views | HTML 2404 views | ?
Siddhartha Ganguly1,*, Trisha Home1,*, Abdulraheem Yacoub1, Suman Kambhampati1, Huidong Shi2, Prasad Dandawate1, Subhash Padhye3, Ashok K. Saluja4, Joseph McGuirk1, Rekha Rao1
1The University of Kansas Cancer Center, Kansas City, KS, USA
2Georgia Regents University, Augusta, GA, USA
3Interdisciplinary Science and Technology Research Academy, University of Pune, Maharashtra, India
4University of Minnesota, Minneapolis, MN, USA
*These authors have contributed equally to this work
Rekha Rao, e-mail: [email protected]
Keywords: HSF1, HSP90, CLL, minnelide
Received: May 26, 2015 Accepted: August 28, 2015 Published: September 10, 2015
CLL is a disease characterized by chromosomal deletions, acquired copy number changes and aneuploidy. Recent studies have shown that overexpression of Heat Shock Factor (HSF) 1 in aneuploid tumor cells can overcome deficiencies in heat shock protein (HSP) 90-mediated protein folding and restore protein homeostasis. Interestingly, several independent studies have demonstrated that HSF1 expression and activity also affects the chaperoning of HSP90 kinase clients, although the mechanism underlying this observation is unclear. Here, we determined how HSF1 regulates HSP90 function using CLL as a model system. We report that HSF1 is overexpressed in CLL and treatment with triptolide (a small molecule inhibitor of HSF1) induces apoptosis in cultured and primary CLL B-cells. We demonstrate that knockdown of HSF1 or its inhibition with triptolide results in the reduced association of HSP90 with its kinase co-chaperone cell division cycle 37 (CDC37), leading to the partial depletion of HSP90 client kinases, Bruton’s Tyrosine Kinase (BTK), c-RAF and cyclin-dependent kinase 4 (CDK4). Treatment with triptolide or HSF1 knockdown disrupts the cytosolic complex between HSF1, p97, HSP90 and the HSP90 deacetylase- Histone deacetylase 6 (HDAC6). Consequently, HSF1 inhibition results in HSP90 acetylation and abrogation of its chaperone function. Finally, tail vein injection of Mec-1 cells into Rag2-/-IL2Rγc-/- mice followed by treatment with minnelide (a pro-drug of triptolide), reduced leukemia, increased survival and attenuated HSP90-dependent survival signaling in vivo. In conclusion, our study provides a strong rationale to target HSF1 and test the activity of minnelide against human CLL.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.